Viatris Inc.
NASDAQ:VTRS · NASDAQ Global Select
-$0.36 today
Vol 19.55M · Avg 10.58M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:VTRS · Revenue to Net Income
Key Ratios
Analysis
$14.6B of revenue converted into -$296.5M of net income for the selected period. Gross margin is 34.4% and net margin is -1.9%, showing how much revenue survives after costs and taxes. EPS is $-0.26, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3B -3.0% | $14.7B -4.5% | $15.4B -5.1% | $16.3B -9.1% | $17.9B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $9.3B +1.9% | $9.1B +1.4% | $9.0B -8.0% | $9.8B -20.7% | $12.3B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $5.0B -10.8% | $5.6B -12.7% | $6.4B -0.9% | $6.5B +16.5% | $5.6B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 35.1% -3.1pp | 38.2% -3.6pp | 41.7% +1.8pp | 40.0% +8.8pp | 31.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $965.9M +19.4% | $808.7M +0.4% | $805.2M +21.6% | $662.2M -2.8% | $681.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $3.8B -14.3% | $4.4B -4.8% | $4.7B +11.3% | $4.2B -7.7% | $4.5B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $7.7B +36.8% | $5.6B -1.0% | $5.7B +16.2% | $4.9B -13.0% | $5.6B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.8B -3.3% | $2.9B +5.6% | $2.7B -9.5% | $3.0B -32.8% | $4.5B | $374.2M | $1.2B | $631.8M |
| EBITDA | -$395.4M -114.0% | $2.8B -19.8% | $3.5B -45.3% | $6.4B +43.7% | $4.5B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -2.8% -21.9pp | 19.1% -3.7pp | 22.8% -16.8pp | 39.6% +14.5pp | 25.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$2.7B -26467.3% | $10.1M -98.7% | $766.2M -52.6% | $1.6B +4849.7% | -$34.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -18.6% -18.7pp | 0.1% -4.9pp | 5.0% -5.0pp | 9.9% +10.1pp | -0.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 | $0 | $0 | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $471.3M -14.3% | $550.0M -4.0% | $573.1M -3.3% | $592.4M -6.9% | $636.2M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.0B -58.2% | -$633.3M -12.4% | -$563.3M -147.0% | $1.2B +290.1% | -$630.4M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$3.7B -488.1% | -$623.2M -407.1% | $202.9M -92.8% | $2.8B +523.4% | -$664.4M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -25.6% -21.4pp | -4.2% -5.5pp | 1.3% -16.0pp | 17.3% +21.0pp | -3.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$150.1M -1464.5% | $11.0M -92.6% | $148.2M -79.8% | $734.6M +21.5% | $604.7M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$3.5B -454.2% | -$634.2M -1259.4% | $54.7M -97.4% | $2.1B +263.8% | -$1.3B | $4.9B | $4.8B | $4.7B |
| Net Margin | -24.6% -20.3pp | -4.3% -4.7pp | 0.4% -12.4pp | 12.8% +19.9pp | -7.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$3 -466.0% | -$1 -1262.3% | $0 -97.3% | $2 +262.9% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$3 -466.0% | -$1 -1270.0% | $0 -97.4% | $2 +262.9% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $1.2B -1.9% | $1.2B -0.6% | $1.2B -1.0% | $1.2B +0.3% | $1.2B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $1.2B -1.9% | $1.2B -1.1% | $1.2B -0.9% | $1.2B +0.7% | $1.2B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Moderna, Inc.
NASDAQ:MRNA
$25.38B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.59B
Exact Sciences Corporation
EXAS
$20.03B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$15.92B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$12.98B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.25B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.10B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.07B
Baxter International Inc.
NYSE:BAX
$10.28B
Regencell Bioscience Holdings Limited
NASDAQ:RGC
$5.94B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does VTRS generate?
Viatris Inc. (VTRS) reported $14.30B of revenue in fiscal 2025.
Is VTRS profitable?
Viatris Inc. (VTRS) reported -$3,514,900,000.00 of net income, with a net margin of -24.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.